Skip to main content

Year: 2022

Michael H. Jenkins Assumes the Role of Orion Energy Systems CEO

Mr. Michael Jenkins, Orion’s new CEO Michael H. Jenkins Assumed the Role of Orion Energy Systems CEO after the retirement of CEO Mike Altschaefl.MANITOWOC, Wis., Nov. 11, 2022 (GLOBE NEWSWIRE) —  Orion Energy Systems, Inc. (Nasdaq: OESX) (Orion Lighting), a provider of energy-efficient LED lighting and controls, maintenance services and electrical vehicle (EV) charging station solutions, announced Michael H. Jenkins, the Company’s Executive Vice President and Chief Operating Officer, has officially assumed the role of Orion’s Chief Executive Officer (CEO) after the retirement of CEO Mike Altschaefl on November 10th. Mike Jenkins is an accomplished executive leader with a strong track record of business and financial achievement built over more than 25 years. He joined Orion last year as part of a long-term strategic leadership...

Continue reading

Release of employee restricted share units in SalMar ASA

Frigivelse av ansattes Restricted Share Units i SalMar ASA (“Selskapet”). 1. Participants in the Company’s RSU program have on November 11th 2022, settled a total number of 118 075 RSUs. Following the release, 118 075 shares will be transferred from the Company’s holding of own shares. Subsequent to the transaction the Company holds 14 286 own shares. 2. Restricted share units released by primary insiders November 11th 2022: – Arthur Wisniewski has received 1 334 shares in the Company– Eva Haugen has received 1 360 shares in the Company– Ståle Eide (related party of primary insider) has received 1 083 shares in the Company– Frode Arntsen has received 2 262 shares in the Company– Håkon Husby has received 984 shares in the Company– Roger Bekken has received 2 313 shares in the Company–...

Continue reading

Skyline Announces Continued Improvement in Operational Results During Q3 2022

TORONTO, Nov. 11, 2022 (GLOBE NEWSWIRE) — Skyline Investments Inc. (the “Company” or “Skyline”) (TASE: SKLN), a Canadian company that specializes in hotel real estate investments in the United States and Canada, published its results for the three and nine months ended September 30, 2022. SUMMARY OF FINANCIAL RESULTSC$000’s For the Three Months EndedSeptember 30, For the Nine Months EndedSeptember 30,2022 2021 2022 2021NOI1 from Hotels & Resorts 7,109 13,814 20,605 28,566NOI from Hotels & Resorts Margin 21% 31% 21% 29%Same Asset Revenue 32,824 24,782 95,641 65,322Same Asset NOI1 5,755 6,472 19,186 18,146Same Asset NOI Margin 18% 26% 20% 28%Adjusted EBITDA2 5,278 11,666 14,871 22,926Adjusted EBITDA Margin 15.2% 25.5% 15% 22.2%Net Income (loss) (4,365) 26,446 (9,452) 28,497FFO1 (488) 3,543 4,649 8,226Shareholders’...

Continue reading

BurgerFi to Report Third Quarter 2022 Financial Results on November 16, 2022

FORT LAUDERDALE, Fla., Nov. 11, 2022 (GLOBE NEWSWIRE) — BurgerFi International, Inc. (NASDAQ: BFI, BFIIW) (“BurgerFi”), owner of one of the nation’s leading fast-casual “better burger” dining concepts through the BurgerFi brand, and the high-quality, casual dining pizza brand under the name Anthony’s Coal Fired Pizza & Wings (“Anthony’s”), will report financial results for the third quarter ended October 3, 2022 on Wednesday, November 16, 2022 before the market opens. Management will host a conference call at 8:30 a.m. Eastern time on the same day to discuss the results.   The conference call will be broadcast live and available for replay on the Company’s Investor Relations website at ir.burgerfi.com. Participants can also access the call using the dial-in details below. Date: Wednesday, November 16, 2022Time: 8:30 a.m. ETToll-free...

Continue reading

Innofactor Plc: Share Repurchase 11.11.2022

Innofactor Plc Announcement 11.11.2022          Innofactor Plc: Share Repurchase 11.11.2022       In the Helsinki Stock Exchange         Trade date 11.11.2022  Bourse trade Buy  Share IFA1V  Amount 3,842 SharesAverage price/ share 0.9760 EURTotal cost 3,749.79 EUR          Innofactor Plc now holds a total of 1 015 042 sharesincluding the shares repurchased on 11.11.2022          On behalf of Innofactor Plc         Nordea Bank Oyj         Janne Sarvikivi Sami Huttunen       Additional information:    Sami Ensio, CEO    Innofactor Plc    Tel. +358 50 584 2029    sami.ensio@innofactor.com         www.innofactor.com       AttachmentInnofactor_11.11_trades

Continue reading

Bavarian Nordic to Present at Jefferies 2022 London Healthcare Conference

COPENHAGEN, Denmark – November 11, 2022 – Bavarian Nordic A/S (OMX:  BAVA) today announced that Paul Chaplin, President & CEO will provide a corporate presentation at the Jefferies 2022 London Healthcare Conference on Thursday, November 17, 2022 at 8:35 am GMT (9:35 am CET). A live and archived webcast of the presentation will be available at https://www.bavarian-nordic.com/investor/events.aspx?event=6652. ContactsEurope: Rolf Sass Sørensen, Vice President Investor Relations & Communications. Phone +45 61 77 47 43 U.S.: Graham Morrell, Paddock Circle Advisors (US), Tel: +1 781 686 9600 About Bavarian NordicBavarian Nordic is a fully integrated vaccines company focused on the development, manufacturing and commercialization of life-saving vaccines. We are a global leader in smallpox vaccines and have been a long-term supplier...

Continue reading

Ålandsbanken Abp: Acquisitions of own shares 11.11.2022

Ålandsbanken Abp  Changes in company’s own shares11.11.2022 at 18:30 EET Ålandsbanken Abp: Acquisitions of own shares 11.11.2022Date 11.11.2022  ExchangeBourse trade   Nasdaq Helsinki Oy (XHEL)Buy  Share class ALBBV  Amount             285  Average price/share 32.9000 EURHighest price/share 32.9000 EURLowest price/share 32.9000 EURTotal price 9,376.50 EUR     The shares held by Ålandsbanken Abp on 11.11.2022:    ALBBV                                    12,988  On behalf of Ålandsbanken Abp Skandinaviska Enskilda Banken AB (Publ) Antti Salakka                      Janne Tiihonen For more information, please contact: Peter Wiklöf, Managing Director and Chief Executive,...

Continue reading

Candel Therapeutics Announces Late-Breaking Oral Presentation at SITC Annual Meeting with Data on CAN-2409 in Combination with Nivolumab in a Phase 1 Mechanistic Clinical Trial in Patients with High-Grade Glioma

Combination of nivolumab and CAN-2409 delivered during neurosurgery was generally well tolerated with no significant added toxicity compared to standard of care Systemic immune activation was observed in peripheral blood following administration of CAN-2409/valacyclovir prior to nivolumab treatment Median overall survival (mOS) for patients with methylated MGMT promoter was 30.6 months for those undergoing gross total resection (GTR) and 12.6 months for those undergoing sub-total resection (STR). For patients with unmethylated MGMT promotor, mOS was 13.2 months and 15.9 months, respectively.NEEDHAM, Mass., Nov. 11, 2022 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical stage biopharmaceutical company developing novel viral immunotherapies, today announced presentation of late-breaking data from a phase...

Continue reading

Rovio Entertainment Corporation: Repurchase of own shares on 11 November 2022

Rovio Entertainment Oyj STOCK EXCHANGE RELEASE 11.11.2022 at 18.45 EET   Rovio Entertainment Corporation – Repurchase of own shares on 11.11.2022   Rovio Entertainment Corporation  In the Nasdaq Helsinki  Date 11.11.2022Exchange transaction BUYShare trading code ROVIOAmount, shares 42464Average price/share, EUR 6,188434Total cost, EUR 262785,65      Rovio now holds a total of 5 982 558 shares including the shares repurchased on 11.11.2022   On behalf of Rovio Entertainment Corporation     OP Corporate Bank PLC  Further information:Timo Rahkonen, VP Investor Relations & Corporate Strategy +358 40 730 3442 RovioIR@rovio.com Distribution:Nasdaq Helsinki LtdKey mediawww.rovio.com About Rovio:Rovio Entertainment Corporation is a global mobile-first games company that creates,...

Continue reading

Global Bioenergies renews equity line with Kepler Cheuvreux to support industrial deployment

Global Bioenergies renews equity line with Kepler Cheuvreux to support industrial deployment Evry, 11 November 2022  Global Bioenergies today announces the renewal of its equity line with Kepler Cheuvreux, a leading European financial services company acting as ISP1 as part of an underwriting agreement. This financing solution with Kepler Cheuvreux has already been a well-proven success for Global Bioenergies: the two-year contract signed in August 2020 raised €13.6 million and the valuation of Global Bioenergies doubled over the same period.   This transaction aims to strengthen the Company’s financial structure. The funds raised will mainly go towards prefinancing the production of Isonaturane® 12 on the new “Horizon 2” line and performing engineering studies for the 2,000 tonne/year Horizon 3 plant, construction of which is to be financed...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.